Summary & Overview
CPT 86408: SARS–CoV–2 Neutralizing Antibody Screening
CPT code 86408 identifies a laboratory assay performed to screen specimens, such as plasma, for neutralizing antibodies to SARS–CoV–2. This molecular/serologic test is clinically significant for assessing functional immune response after infection or vaccination and has implications for epidemiology, public health surveillance, and select clinical decision-making. The code captures the technical component of the neutralizing antibody screening performed in a diagnostic laboratory setting.
Key payers included in the national discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find an overview of the clinical purpose of the test, common sites of service, typical billing considerations, and which payers commonly recognize and reimburse neutralizing antibody screening in different clinical scenarios. The publication outlines benchmark billing practices, common modifier use where applicable, and policy considerations affecting coverage and coding for laboratory-based neutralizing antibody assays. The summary provides clinical context for how this test is used and what stakeholders should expect in terms of coding and payer interactions. Data not available in the input is noted where payer-specific policy detail, associated taxonomies, and ICD-10 linkage would normally appear.
Billing Code Overview
CPT code 86408 describes a technical laboratory test to screen a specimen (for example, plasma) for neutralizing antibodies against SARS–CoV–2, the virus that causes COVID-19. The service involves laboratory analysis to detect functional antibodies that can inhibit viral activity, providing clinical information about immune response following infection or vaccination.
Service type: Laboratory serologic testing — neutralizing antibody screening
Typical site of service: Clinical diagnostic laboratory or hospital laboratory (specimen collected in an outpatient, inpatient, or collection center; testing performed in a laboratory setting)
Clinical & Coding Specifications
Clinical Context
A 45-year-old outpatient presents for evaluation of post-infection immune response following confirmed SARS–CoV–2 infection three months prior. The clinician orders a neutralizing antibody screen to assess the presence and level of functional antibodies in plasma that can inhibit viral entry. A phlebotomy technician collects a plasma specimen and sends it to the clinical laboratory. In the lab, a medical technologist or lab analyst performs the technical neutralizing antibody assay (a virology neutralization or surrogate neutralization test) and documents results in the laboratory information system. Results are routed to the ordering provider for interpretation and potential patient counseling. Typical site of service is a hospital clinical laboratory, independent reference laboratory, or large outpatient hospital-based phlebotomy collection center. Service type: Clinical laboratory diagnostic immunology/virology testing for neutralizing antibodies to SARS–CoV–2.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician or pathologist interpretation of the test result separate from the lab's technical component. |
TC | Technical component |